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Elevated preoperative serum levels of
collagen I carboxyterminal telopeptide
predict better outcome in early-stage
luminal-B-like (HER2-negative) and
triple-negative subtypes of breast
cancer
Anniina Ja¨a¨skela¨inen1,2 , Arja Jukkola3, Juha Risteli4,5,
Kirsi-Maria Haapasaari2 and Peeter Karihtala1
Abstract
Type 1 collagen is an important part of the extracellular matrix and changes in its metabolism and distribution are essen-
tial in breast cancer induction and progression. Serum concentrations of type 1 collagen synthesis (aminoterminal pro-
peptide (PINP)) and degradation markers (carboxyterminal telopeptide (ICTP)) have previously been studied in early
and metastatic breast cancer, but no data are available on specific breast cancer subtypes. We assayed 662 preoperative
serum samples for PINP and ICTP and 109 postoperative serum samples for ICTP. The results were linked to prospec-
tively collected clinical data and the cases were divided into breast cancer subtypes for survival analyses. The concentra-
tions of both pre- and postoperative ICTP serum levels increased linearly from ductal in situ carcinoma to stage I–II
tumors, stage III tumors, and finally to those with concomitant primary metastases (preoperative ICTP, p = 0.009; post-
operative ICTP, p = 0.016). High-preoperative ICTP levels were associated with better breast cancer-specific survival in
connection with luminal-B-like (HER2-negative) tumors (p = 0.017), which was confirmed in Cox regression analysis
(relative risk = 3.127; 95% confidence interval = 1.081–9.049, p = 0.035), when T-class (relative risk = 4.049; 95% confi-
dence interval = 1.263–12.981; p = 0.019) and nodal status (relative risk = 3.896; 95% confidence interval = 1.088–13.959;
p = 0.037) were included in the analysis. In patients with triple-negative breast cancer, a high-preoperative ICTP level was
a significant predictor of local relapse-free survival in univariate (p = 0.0020) and multivariate analyses (relative risk =
13.04; 95% confidence interval = 1.354–125.5; p = 0.026; for T-class, relative risk = 2.128 and 95% confidence interval =
0.297–15.23; p = 0.452; for N-class, relative risk = 0.332 and 95% confidence interval = 0.033–3.307; p = 0.347). A preo-
peratively elevated serum ICTP level appears to be an important marker of better prognosis in triple-negative breast
cancer and luminal-B-like (HER2-negative) subtypes.
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Introduction
Breast cancer is the most common cancer among
women worldwide, with 90% 5-year overall survival
(OS) in Finland, for instance.1,2 Because of the increas-
ing rates of morbidity and mortality associated with
this disease, patient-tailored therapy strategies, identifi-
cation of new prognostic markers, therapeutic targets,
and new therapeutic approaches are still needed.
The extracellular matrix (ECM) of the tumor micro-
environment (TME) controls various aspects of
tumor-cell behavior such as proliferation, apoptosis,
migration, and invasion.3 Type I collagen is the most
abundant ECM protein, playing an essential role in
maintaining tissue integrity. This protein is able to
interact with several cell-surface receptors and it regu-
lates intracellular signaling in pathological conditions.
It downregulates cell proliferation, induces apoptosis,
promotes survival, and protects cancer cells against
chemotherapy.4 Breast cancer is characterized by a
dense reactive stroma associated with extensive col-
lagen deposits.5 Alterations in the structural organiza-
tion of type I collagen occur during the first phases of
breast cancer development, promoting local invasion.6
Changes in the ECM in breast cancer tissue can be
observed by using serum markers of type 1 collagen
metabolism.7 Two markers used for this purpose are
the aminoterminal propeptide of type I procollagen
(PINP), which reflects human type I collagen synthesis
and the crosslinked carboxyterminal telopeptide of type
1 collagen (ICTP), which reflects type I collagen degra-
dation.8 Serum concentrations of both ICTP and PINP
have previously been shown to be increased in samples
collected from breast cancer patients.7,9,10 PINP and
ICTP are widely studied markers of bone turnover and
their clinical use is wide, being investigated in non-
malignant diseases such as osteoporosis and rheuma-
toid arthritis, and malignant conditions such as meta-
static breast and prostate cancer.9,11–14
Breast cancers can be divided into five intrinsic sub-
types.15 Surrogate characterization of breast cancer
intrinsic subtypes following the European Society for
Medical Oncology (ESMO) Clinical Practice
Guidelines results in the following five molecular sub-
types: (1) luminal-A-like (estrogen- and progesterone-
receptor-positive, HER2-negative, low proliferation);
(2) luminal-B-like, HER2-negative (estrogen-receptor-
positive, HER2-negative and either high proliferation
or progesterone-receptor-negative); (3) luminal-B-like,
HER2 positive (estrogen-receptor-positive, HER2-posi-
tive); (4) HER2 overexpression (estrogen- or progester-
one-receptor-negative, HER2-positive); and (5) triple-
negative (estrogen- or progesterone-receptor-negative,
HER2-negative).16 Within these categories, there are
many heterogeneous groups. Alternatively to immuno-
histochemical surrogates, the exact subtype can be
determined by gene expression profiling, which, how-
ever, is much more resource-consuming.
An important aspect of treating breast cancer is
detecting the tumors that will locally relapse or metas-
tasize despite treatment and early diagnosis. As breast
cancer subtypes differ in their tendency to develop
metastases, earlier evidence encourages examination of
how changes in the ECM differ among subtypes.
Reflecting these changes, a new clinical tool could be
use of biological serum markers such as PINP and
ICTP, levels of which have been shown to be elevated
in patients with aggressive breast cancer.9
The purpose of this study was to investigate changes
of type I collagen metabolism in the connective tissue of
breast cancer patients and assess them as potential prog-
nostic factors of breast cancer subtypes. For the first
time, these type I collagen metabolism markers were
linked to breast cancer subtypes in a prospective setting.
Materials and methods
Patients
The study population consisted of 662 breast cancer
patients who were treated at Oulu University Hospital
in 2003–2013 (Table 1). The patient data were prospec-
tively collected from the archives of Oulu University
Hospital. Follow-up time was defined as being from the
day of operation to the last day of updating the data
(15 July 2017). Median follow-up time was 72months.
Patients and tumors were classed using TNM classifica-
tion and histopathological classification according to
the World Health Organization (WHO) (Table 2).17,18
Immunohistochemistry
Subtypes were confirmed by using immunohistochemis-
try (IHC) on surgically removed tumors at the
Department of Pathology, Oulu University Hospital.
Immunohistochemical scoring was recorded in connec-
tion with postoperative pathoanatomical diagnosis.
Tumors were paraffin-embedded, cut, and stained with
hematoxylin and eosin for histological analysis.
Expression levels of nuclear estrogen and progesterone
receptors (ERs and PRs) and Ki-67 were analyzed as
described previously by Karihtala et al.19 Tumor sam-
ples expressing nuclear ER or PR in more than 9% of
invasive tumor cells were considered to be steroid
receptor-positive prior to 2010. The clinical standard
for defining ER and PR receptor status by IHC chan-
ged at the Department of Pathology around 2010.
Tumor samples obtained in 2010 and later on and
2 Tumor Biology
expressing nuclear ER or PR receptors in more than
1% of invasive tumor cells were considered receptor-
positive. Eight (1.2%) of the surgically removed tumors
had invasive tumor cells expressing low-grade (1%–
9%) nuclear ER. Tumor cells in the triple-negative
breast cancer (TNBC) group did not express any ER or
PR positivity according to the definition stated above.
If a specimen expressed a membranous HER2-positive
result in IHC (1+ to 3+ on a scale of 0 to 3+ ),
HER2 gene amplification status was determined by
using chromogenic in situ hybridization. Specimens
with six or more gene copies of HER2 in the cells were
considered HER2-positive.20 Of the 662 cases, 41
(6.2%) were classified in the ductal carcinoma in situ
(DCIS) subgroup and 621 patients (93.8%) were diag-
nosed with invasive breast cancer. Of 621 patients, 612
patients (92.4%) were diagnosed with invasive breast
cancer with no primary metastases and 9 patients
Table 1. Patient characteristics.
N (%)
T-class 621 (100.0)
T1 399 (64.3)
T2 197 (31.7)
T3 19 (3.1)
T4 1 (0.2)
Missing 5 (0.8)
N-class 621 (100.0)
N0 383 (61.7)
N1 172 (27.7)
N2 46 (7.4)
N3 16 (2.6)
Missing 4 (0.6)
M-class 621 (100.0)
M0 608 (97.9)
M1 9 (1.5)
Missing 4 (0.6)
Histopathology 662 (100.0)
Ductal 459 (69.3)
Lobular 91 (13.7)
Medullary 5 (0.8)
Tubular 10 (1.5)
DCIS 41 (6.2)
Other 54 (8.2)
Missing 2 (0.3)
Histopathological grade 621 (100.0)
Grade 1 103 (16.6)
Grade 2 298 (48.0)
Grade 3 175 (28.2)
Not exactly defined 22 (3.5)
Missing 23 (3.7)
ER status 621 (100.0)
Negative (0%) 93 (15.0)
Weak (1%–9%) 16 (2.6)
Moderate (10%–59%) 26 (4.2)
High (.59%) 477 (76.8)
Not exactly defined 6 (1.0)
Missing 3 (0.5)
PR status 621 (100.0)
Negative (0%) 150 (24.2)
Weak (1%–9%) 80 (12.9)
Moderate (10%–59%) 66 (10.6)
High (.59%) 307 (49.4)
Not exactly defined 15 (2.4)
Missing 3 (0.5)
HER2 status 621 (100.0)
HER2-positive (CISH) 62 (10.0)
HER2-negative 555 (89.4)
Not available 4 (0.6)
Ki-67 status 621 (100.0)
Negative (\5%) 42 (6.8)
Weak (5%–14%) 276 (44.4)
Moderate (15%–30%) 139 (22.4)
High (.30%) 141 (22.7)
Not exactly defined 18 (2.9)
Not available 5 (0.8)
Breast cancer subtypes 662 (100.0)
Triple-negative 68 (10.3)
HER2 overexpression 26 (3.9)
Luminal-B-like (HER2-positive) 35 (5.3)
Luminal-A-like 287 (43.4)
Luminal-B-like (HER2-negative) 203 (30.7)
(continued)
Table 1. Continued
N (%)
Other 2 (0.3)
Noninvasive 41 (6.2)
Local relapse 621 (100.0)
No local relapse 589 (94.8)
Local relapse 32 (5.2)
Distant metastases 621 (100.0)
No distant metastases 562 (90.5)
Bone metastases 20 (3.2)
Lung metastases 7 (1.1)
Liver metastases 3 (0.5)
Multiple metastases 22 (3.5)
Other distant metastases 7 (1.2)
DCIS: ductal carcinoma in situ; PR: progesterone receptor; ER: estrogen
receptor.
Table 2. Treatments.
Adjuvant chemotherapy 621 (100.0%)
Anthracycline + taxane 132 (21.3%)
Anthracycline 136 (21.9%)
Other chemotherapy 46 (7.4%)
Trastuzumab + chemotherapy 39 (6.3%)
No adjuvant chemotherapy 266 (42.8%)
Missing 2 (0.3%)
Adjuvant radiation therapy (RT) 621 (100.0%)
Received RT 534 (86.0%)
No RT 87 (14.0%)
Adjuvant hormonal therapy 621 (100.0%)
Tamoxifen 169 (27.2%)
Aromatase inhibitor 221 (35.6%)
Tamoxifen + goserelin 2 (0.3%)
Aromatase inhibitor + goserelin 2 (0.3%)
Other endocrine therapy 12 (1.9%)
No endocrine therapy 212 (34.1%)
Missing 3 (0.5%)
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(1.4%) had radiologically confirmed metastases at the
time of diagnosis (Table 1).
Clinicopathological characteristics
Clinicopathological breast cancer surrogate definitions
of intrinsic subtypes followed ESMO Guidelines.21
Luminal-A-like carcinomas showed ER and PR expres-
sion, Ki-67 \15%, and no HER2 overexpression
(n=287, 43.4%). Luminal-B-like (HER2-negative)
carcinomas were ER-positive and HER2-negative, and,
in addition, showed either Ki-67 .15% or were PR-
negative (n=203, 30.7%). Luminal-B-like (HER2-pos-
itive) tumors expressed ER and overexpressed HER2
(n=35, 5.3%). Triple-negative breast carcinomas were
defined as tumors with negative ER, PR, and HER2
expression (n=68, 10.3%). HER2-positive (non-lumi-
nal) cases showed HER2 overexpression without ER or
PR positivity (n=26, 3.9%). Two cases (0.3%) could
not be included in any of the above subgroups accord-
ing to the stated characteristics (Table 1).
Serum samples
Preoperative serum samples were collected from all
study participants on the day of their operation or the
day before, and postoperative serum samples were col-
lected during follow-up visits at Oulu University
Hospital. The timeframe for postoperative samples ran-
ged from 2days up to 1430 days after surgery. The
median time between pre- and postoperative samples
was 40.5 days. The samples were stored at –20C until
use. All 662 preoperative chemiluminescence assays
(CLIAs) succeeded, resulting in defined PINP concen-
trations. With preoperative ICTP assays, the success
rate was a little lower, that is, a defined concentration
in 644 (97.3 %) serum samples. Of the 662 preoperative
samples, 41 (6.4%) showed an increased ICTP serum
concentration in comparison with the established refer-
ence values of 2.1–5.6mg/L for women (over the age of
18 years). In these cases, the postoperative ICTP con-
centration was defined according to that in the first
follow-up sample. We randomly selected 68 controls
for postoperative ICTP analysis among the sera that
did not show an increased ICTP concentration in the
respective preoperative serum sample. Assay of all 109
postoperative serum samples resulted in a defined
ICTP concentration. The median preoperative concen-
tration of PINP was 40.21ng/mL and pre- and post-
operative ICTP concentrations were 4.471 and
4.749mg/L, respectively. Invasive cases with no distant
metastases at the time of diagnosis were included. In
the analysis performed to compare serum ICTP levels
at different stages of breast cancer, we included DCIS
cases as well as those with distant metastases at the
time of diagnosis.
PINP automated assay
PINP concentrations in serum samples were assessed
by using the IDS-iSYS Intact PINP assay Multi-
Discipline Automated System analyzer (IDS iSYS
Intact PINP, Immunodiagnostics Systems, Boldon,
UK). It is an automated assay based on CLIA technol-
ogy and designed for quantitative determination of
intact PINP in human serum. The method has been
previously described in detail.22 Serum samples of
20mL were used in each analysis that we carefully con-
ducted according to the manufacturer’s instructions.
The CLIA involves the use of two monoclonal antibo-
dies, a biotinylated anti-PINP monoclonal antibody
and an acridinium-labeled monoclonal antibody. These
are combined with streptavidin-labeled magnetic parti-
cles in assay buffer. Light is emitted by the acridinium
label which is directly proportional to the concentra-
tion of intact PINP in the original sample. For calculat-
ing the concentrations of intact PINP a four-parameter
logistic curve is used. The calibrators are measured in
triplicate and the controls in duplicate.22 PINP auto-
mated assays were performed in February 2017 and
May 2017.
ICTP radioimmunoassay
Serum ICTP concentrations were measured by using
quantitative radioimmunoassays (RIAs)—commer-
cially available kits (UniQ ICTP RIA, Orion
Diagnostica, Espoo, Finland). The assays were con-
ducted in the laboratory of the Department of Clinical
Chemistry (Oulu University Hospital). The method is
based on the competitive RIA technique using I125-
labeled human ICTP antigens (tracer), non-labeled
human ICTP antigens (sample) and polyclonal rabbit
antibodies. Both labeled and non-labeled ICTP anti-
gens compete for binding to the antibody (antiserum),
which has a limited amount of binding sites. After
separating the remaining free antigen, the amount of
labeled antigen is inversely proportional to the amount
of actual ICTP in the sample. The principals of this
assay have been described previously by Risteli et al.23
Duplicate serum samples of 100mL were used in this
assay, which was conducted according to the manufac-
turer’s instructions. The radioactivity of each sample is
measured by using a gamma counter and the results
determined via use of the calibration curve created in
each assay run. ICTP RIAs of preoperative serum sam-
ples were performed in February 2017. The postopera-
tive ICTP RIAs were performed in May 2017.
Statistical analysis
Statistical analysis was carried out by using IBM SPSS
Statistics software, v. 23.0.0.0 (IBM Corporation,
4 Tumor Biology
Armonk, NY, USA). The Mann–Whitney U test and the
Kruskal–Wallis test were used to assess the significance of
associations. The relationships between PINP and ICTP
serum concentrations were assessed by using Spearman’s
correlation coefficient. Survival was analyzed by using
Kaplan–Meier curves and the log-rank test. Median
serum levels were used as cut-off values in survival analy-
sis and patients with distant metastases at the time of
diagnosis were excluded from these analyses. Disease-free
survival (DFS) was calculated from the date of diagnosis
to the date of the first confirmed relapse, either local or
distant. Relapse-free survival (RFS) was defined as the
time from diagnosis to relapse in resected breast, chest
wall, or in the ipsilateral axilla. Breast cancer-specific sur-
vival (BCSS) was calculated from the date of diagnosis to
the time of death due to breast cancer. For multivariate
analyses, we used Cox multivariate regression analysis
(co-variates T-class and N-class). Probability values less
than 0.05 were considered significant.
Ethics approval
The study was approved by The Regional Ethics
Committee of the Northern Ostrobothnia Hospital
District (123/2016). The principles of the Declaration
of Helsinki were followed in this study.
Results
ICTP and tumor invasiveness
Patient characteristics are described in Table 1. Most of
the patients were diagnosed with ductal carcinoma
(69.3%) and T1 tumors (64.3%), and only 37.7% were
node-positive at the time of diagnosis. ER status was
positive in most of the tumors (84.6%). Ten percent of
the patients were diagnosed with HER2-positive disease.
The serum concentrations of both pre- and postoperative
ICTP increased linearly from cases of in situ carcinoma
to those patients with metastases at the time of diagnosis
(Figure 1). Preoperative mean ICTP concentrations rose
as follows: stage 0, 3.43mg/L (range=2.21–7.56mg/L);
stages I–II, 3.81mg/L (range=1.55–25.4mg/L); stage
III, 4.15mg/L (range=1.56–28.6mg/L); and stage IV,
4.75mg/L (range=2.23–12.9mg/L) (p=0.009).
Respectively, postoperative mean ICTP concentrations
were as follows: DCIS, 4.19mg/L (range=3.71–4.48mg/
L); stages I–II, 5.23mg/L (range=2.60–17.0mg/L);
stages II–III, 6.15mg/L (range=3.20–4.7mg/L); stage
IV, 14.42mg/L (p=0.016). There was only one post-
operative sample in the stage IV group.
Traditional prognostic factors were re-formatted as
two-class variables for the analyses. T-class was divided
into T1 or T2–4 classes, and nodal status to either
nodal negativity or positivity. Histopathological grade
was divided to either grades 1–2 or grade 3. Elevated
postoperative ICTP concentrations were associated
with increased tumor size (p=0.025), nodal involve-
ment (p=0.01), and a higher histopathological grade
(p=0.038) (Table 3). Elevated preoperative ICTP con-
centrations were associated with nodal involvement
(p=0.036). A high preoperative ICTP concentration
was associated with invasive breast cancer (p=0.012)
compared with in situ carcinoma, whereas higher preo-
perative PINP concentrations were found in DCIS
compared with invasive carcinomas (p=0.040).
Correlations between type I collagen markers in
different breast cancer subtypes
None of the studied markers were associated with a spe-
cific breast-cancer subtype. Preoperative serum PINP
concentrations were correlated (Spearman’s correlation)
with pre- and postoperative serum ICTP concentrations
Figure 1. Correlations between tumor stage and (a) preoperative ICTP and (b) postoperative ICTP concentrations. Lines
represent 95% confidence intervals.
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(Table 4). In addition, preoperative ICTP concentra-
tions were correlated with postoperative ICTP concen-
trations. Correlations were carried out separately in the
population of 612 invasive cases with no primary metas-
tases and in different breast cancer subtypes.
Survival analysis
A high preoperative ICTP level was associated with
better BCSS, but only in the patients with luminal-B-
like (HER2-negative) tumors (in univariate analysis
p=0.017) (Figure 1). This was confirmed in Cox
regression analysis (relative risk (RR)=3.127; 95%
confidence interval (CI)=1.081–9.049; p=0.035),
when T-class (RR=4.049; 95% CI=1.263–12.981;
p=0.019) and nodal status (RR=3.896; 95%
CI=1.088–13.959; p=0.037) were included in the
analysis. A high preoperative ICTP level was also a sig-
nificant predictor of local RFS in univariate
(p=0.0020) and multivariate analyses (RR=13.04,
95% CI=1.354–125.5, p=0.026; for T-class,
RR=2.128, 95% CI=0.297–15.23, p=0.452; for N-
class, RR=0.332, 95% CI=0.033–3.307, p=0.347),
but only in the patients with TNBC. Preoperative
serum PINP concentrations were not associated with
BCSS, DFS, or RFS (Figure 2).
Discussion
This is the first prospective study in which early-stage
breast cancer patients have been placed in subgroups
on the basis of breast cancer subtypes and concentra-
tions of their serum type I collagen synthesis and degra-
dation markers compared. As the main finding,
elevated preoperative serum ICTP levels were found to
be associated with better prognosis in luminal-B-like
(HER2-negative) early breast cancer. In addition,
exceptionally dismal local RFS was observed with
TNBC patients with low preoperative ICTP levels.
Furthermore, our results indicate that in higher stages
of breast cancer, preoperative and postoperative serum
ICTP concentrations are elevated.
Elevated preoperative serum ICTP levels have previ-
ously been shown to be associated with poor outcomes
in breast cancer. Imamura et al.10 noticed worse RFS,
but only in a subgroup of postmenopausal women.
Keskikuru et al.24 reported that higher preoperative
ICTP levels were associated with poor DFS and OS.
However, that study was a relatively small retrospective
study and up to 35% of the patients developed recur-
rence during the 62-month follow-up time. Also,
Imamura et al. noted that 10.7% of their patients
developed metastatic disease during 23.6months of fol-
low up. On the basis of AZURE trial data, high preo-
perative ICTP levels predicted bone recurrence, but
were not associated with other endpoints.25 The con-
trast between the results of earlier studies and ours
could be, at least to some extent, explained by the selec-
tion of patients. Our study is prospective, concerning
612 patients with non-metastatic early-stage breast can-
cer, with long-term follow-up. Serum ICTP levels were
not associated with survival in the study population as
a whole, but only within certain, preselected subgroups.
Only 9.5% of our patients developed distant metastases
during a 72-month follow-up period, which is well in
line with modern treatment results.
Table 3. Associations (p values) between serum PINP and ICTP concentrations versus prognostic factors in the study population.
Preoperative PINP Preoperative ICTP Postoperative ICTP
T-index ns ns 0.025
N-index ns 0.036 0.01
Histopathological grade ns ns 0.038
Invasive or not 0.040 0.012 ns
Table 4. Correlations between preoperative PINP and pre-
and postoperative ICTP concentrations in different breast
cancer subgroups (stages 0 and IV excluded).
ICTP
preoperative
ICTP
postoperative
Invasive breast cancer
PINP preoperative p = 3.853 10–10
r = 0.245
p = 0.021
r = 0.226
ICTP preoperative p = 1.033 10–13
r = 0.651
Luminal-A-like
PINP preoperative p = 0.000043
r = 0.244
p = 0.015
r = 0.328
ICTP preoperative 1.493 10–7
r = 0.644
Luminal-B-like (HER2-negative)
PINP preoperative p = 0.000178
r = 0.269
ns
ICTP preoperative p = 0.00222
r = 0.583
TNBC
PINP preoperative p = 0.002
r = 0.381
ns
ICTP preoperative p = 0.0014
r = 0.583
TNBC: triple-negative breast cancer.
6 Tumor Biology
High preoperative ICTP serum concentrations have
also previously been connected to poor prognosis in
other cancers. Simojoki et al.26 presented evidence that a
higher preoperative ICTP serum concentration predicts a
poor outcome in epithelial ovarian cancer. Nurmenniemi
et al.27 found that a higher serum ICTP concentration
predicted worse survival in cases of head and neck squa-
mous cell carcinoma (HNSSC), and ICTP concentrations
were continuously elevated from stage I to stage IV dis-
ease. This finding parallels ours, since we observed that
both preoperative and postoperative ICTP levels
increased along with stage (stages 0–IV).
The reason that a high ICTP level predicts a better
outcome in TNBC and luminal-B-like (HER2-negative)
subgroups could be linked to collagen I metabolism
and organization of the ECM. Cancer cells invade and
migrate through the ECM on their metastatic journey.
Hypoxia and hypoxia-inducible factors (HIFs) can
facilitate invasion and metastasis by upregulation of
degradative enzymes and remodeling of the ECM.28
Collagen I (Col1) fibers represent the main component
of the ECM. In breast cancers, a high collagen density
has been associated with increased malignancy and also
tumor aggressiveness.6 Col1 degradation is mostly due
to matrix metalloproteinases MMP-1 and MMP-14.29
In a recent paper, Goggins et al.30 suggested that a
decrease of MMP-1 and MMP-14 in HIF-silenced
TNBC cells would prevent Col1 degradation and
increase the amount of type I collagen fibers. Also, a
reduction in lysyl oxidase (LOX) protein expression in
HIF-downregulated tumors suggested that more non-
crosslinked collagen I fibers are present despite an over-
all increase in fiber density. Lysyl oxidases are enzymes
that catalyze the cross-linking of Col1. LOX expression
was found to induce hypoxia and is regulated by HIF-1
in TNBC.30 Usually, in tumors that are not HIF-
silenced, type I collagen metabolism is active, with non-
reduced amounts of MMPs, causing increased collagen
I degradation reflected in an elevated serum level of
ICTP. Along with the absolute amount of collagen in
breast cancer tissue, collagen fiber structures are impor-
tant in different stages of tumor-cell invasion.6 As can-
cer cells have been shown to move along radially
aligned collagen fibers, an increase of Col1 fibers does
not automatically result in increased metastatic activity
or aggressiveness of tumor cells.6,30 Molecular
Figure 2. Kaplan–Meier curves showing BCSS in the (a) whole population and (b) separately in the patients with the luminal-B-like
(HER2-negative) subtype. RFS in the (c) whole study cohort and (d) separately in cases of triple-negative breast cancer. Patients with
distant metastases at the time of diagnosis were excluded from the survival analyses.
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mechanisms within cancer cells do not solely define
cancer behavior, and cellular and molecular compo-
nents of the ECM and its three-dimensional structure
play an essential role.31,32 This reinforces the impor-
tance of ECM organization in different breast cancer
subtypes, as Col1 fiber alignment is a determinant of
cancer progression.6 Earlier evidence concerning TACS
(patterns of collagen 1 fiber bundles at the tumor–host
interface) and their association with cancer progression
and prognosis encourages further study of ECM orga-
nization in different breast cancer subtypes.6,33 To sum-
marize, it is possible that in some subgroups of breast
cancer (TNBC, luminal-B-like (HER2-negative)), the
collagen matrix can be protective and in those tumors
increased degradation of collagen can be a marker of
good prognosis, as demonstrated in our study.
The luminal B (HER2-negative) subgroup is hetero-
geneous and may also have a heterogeneous prog-
nosis.34–36 It is known that the microenvironment is
closely related to the development of these tumors.37 As
far as we know, there is no previous research concern-
ing the relationship between the collagen metabolism
markers PINP and ICTP and the luminal B (HER2-
negative) subtype. However, Zhu et al.38 have described
the interactions between cancer cells, cytokines, and
ECM collagen IV (as a prognostic marker) in the lumi-
nal B (HER2-negative) subtype.
Our study obviously has some weaknesses. We were
not able to define exact biological subtypes of breast
cancer by genotyping and we relied on immunohisto-
chemical surrogates of these subtypes. Neither did we
know the menopausal status of the patients, which
potentially may have affected the results. The cut-off
point for ER positivity changed in international guide-
lines from 10% to 1% during collection of the cohort,
which resulted in different definitions of subgroups in
some rare cases.
In conclusion, we were able to determine, for the
first time, with this prospectively collected data and
long-term follow-up, that a high preoperative serum
ICTP concentration is associated with better local-RFS
(in the TNBC group) and better BCSS (in the luminal-
B-like, HER2- negative subgroup) by way of a partly
unclear mechanism. Data from our study yield impor-
tant information for the first time in different breast-
cancer subtypes that the collagen I degradation marker
ICTP is an important marker of better prognosis.
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